

Development of a 'two hit'± in vivo autologous platelet transfusion model in healthy volunteers

Gepubliceerd: 28-03-2017 Laatste bijgewerkt: 15-05-2024

In the presence of a 'first hit'± an aged apheresis platelet transfusion is able to induce a mild form of ALI

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON26852

Bron

NTR

Verkorte titel

DIVA

Aandoening

Transfusion related acute lung injury (TRALI), Metabolic recovery of transfused thrombocytes after storage

Ondersteuning

Primaire sponsor: Academisch Medisch Centrum, Amsterdam, The Netherlands

Overige ondersteuning: Sanquin Blood Supply Foundation, Amsterdam The Netherlands

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Test the hypothesis that in the presence of a 'first hit'± an aged apheresis platelet transfusion is able to induce a mild form of ALI.

Toelichting onderzoek

Achtergrond van het onderzoek

Transfusion related acute lung injury (TRALI) is the leading cause of transfusion related morbidity and mortality. TRALI is thought to be a 'two hit'± event. The first event is the underlying condition of the patient, often sepsis or an infection, resulting in priming of neutrophils. The second event is the transfusion of a blood product. Additional research is needed to determine whether the use of fresh cell-containing blood products may be an additional measure to reduce TRALI.

The aim of this study is to develop a TRALI model in healthy volunteers. Subjects are extensively screened at the AMC and Sanquin (including medical history, physical examination, ECG, laboratory testing, spirometry and DLCO, X-thorax). If the subjects are enrolled in the study, they are randomized for the first hit in two groups, one receiving LPS 2ng/kg, the other group will receive saline. For the second hit the subjects are randomized between autologous fresh platelets (2 days old) and autologous stored platelets (7 days old). A small portion of the platelets will be biotinylated to identify the transfused platelets from the circulating population. 6 h after the transfusion spirometry, DLCO and X-thorax will be repeated and a broncho alveolar lavage will be performed to test whether the subjects did develop TRALI.

After transfusion multiple blood samples will be drawn to measure markers of inflammation, neutrophil activation and coagulation activation are measured to confirm whether we have developed a model of TRALI. Furthermore, biotinylated platelets will be isolated by flow cytometry to test metabolic recovery using liquid chromatography and mass spectrometry.

Doel van het onderzoek

In the presence of a 'first hit'± an aged apheresis platelet transfusion is able to induce a mild form of ALI

Onderzoeksopzet

1) Prior to experiment:

- Screening twice, at AMC and Sanquin
- Donating 1 unit of platelets 2 or 7 days prior to experiment

2) Experiment day: subject will be admitted for one day at the intensive care

3) Follow up

- 2 days, 4 days and 3 months after experiment day

Onderzoeksproduct en/of interventie

All subjects will be screened (medical history, physical examination, ECG, blood examination, spirometry, DLCO, chest x-ray) by the research physician of our hospital and of Sanquin Blood Bank prior to involvement in the experiment. All included healthy volunteers (n=36) will donate 1 unit of apheresis PLTs (approximately 150 - 400 ml). Processing and storage will be according to Sanquin Blood Bank protocol. Prior to transfusion, stored PLTs will be biotinylated to allow their identification by flow cytometry. In short, stored PLTs will be labelled with Sulfo-NHS biotine (5 µg/ml). Subsequently on the study day healthy volunteers will receive a γ °first hit $\pm$ of either E. coli lipopolysaccharide (LPS) 2 ng/kg i.v. (n=18) or NaCl 0.9% 10 ml intravenously (n=18). Two hours after the γ °first hit $\pm$ the volunteers will receive an autologous transfusion of 1 unit of fresh (2 day storage) biotinylated PLTs or an autologous transfusion of 1 unit aged biotinylated (7 days of storage) PLTs or an equivalent volume of saline 0.9% infusion. The transfusion itself will be performed in 30-60 minutes. During the experiment subjects will be monitored for blood pressure and arterial oxygenation using an indwelling arterial line. Blood samples will be drawn from an indwelling artery line prior to the γ °first hit $\pm$, prior to the transfusion, 10 minutes, 0,5, 1, 2, 4 and 6 hours after transfusion. Furthermore, 6 hours after transfusion spirometry and DLCO measurement will be repeated. A chest x-ray and a directed bronchoalveolar lavage (BAL) will be performed 6 hours after transfusion. In the BAL-fluid and plasma samples markers of inflammation, neutrophil activation and coagulation activation are measured to confirm whether we have developed a model of TRALI. Two days, four days and three months after the study day a venous sample of 4 ml will be collected to monitor platelet kinetics and to measure prevalence of biotin antibodies.

Contactpersonen

Publiek

Sanne De Bruin
Amsterdam
The Netherlands

Wetenschappelijk

Sanne De Bruin
Amsterdam
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- 1) Healthy male volunteer
- 2) Age $\geq$ 18 years $<$ 35 years

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- 1) No informed consent
- 2) Any abnormal test result during the screening prior to inclusion of the study (medical history, physical examination, ECG, blood and urine examination, spirometry, DLCO measurement, chest x-ray).
- 3) History of drugs or alcohol abuse
- 4) Any present medication use on prescription
- 5) Smoking $<$ 6 months
- 6) History of blood donation $<$ 3 months
- 7) Blood loss of more 500 ml $<$ 3 months
- 8) Previously transfused
- 9) Participation in any other medical drug study $<$ 3 months
- 10) Participation in previous volunteer studies using LPS

Onderzoeksopzet

Opzet

Type: Interventie onderzoek

Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Open / niet geblindeerd
Controle:	Geneesmiddel

Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-04-2017
Aantal proefpersonen:	36
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies	
Datum:	28-03-2017
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 55634
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL6318
NTR-old	NTR6493
CCMO	NL50117.018.14
OMON	NL-OMON55634

Resultaten